Compound 10 (Fig. 3) having pomalidomide and a phenyl-pyrazole-based BTK inhibitor exhibited potent and selective activity in degradation of BTK in Burkitt lymphoma Ramos and leukemia THP-1 cells [66]. The gene discussed is BTK; the disease is leukemia.